The Vanguard Group 13D and 13G filings for Theravance Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 5:53 pm Unchanged |
2024-09-30 | 13G | Theravance Biopharma, Inc. TBPH |
The Vanguard Group | 2,051,689 4.190% |
0 (Unchanged) |
Filing |
| 2024-11-04 3:33 pm Unchanged |
2024-09-30 | 13G | Theravance Biopharma, Inc. TBPH |
The Vanguard Group | 2,051,689 4.190% |
0 (Unchanged) |
Filing |
| 2024-11-04 2:10 pm Sale |
2024-09-30 | 13G | Theravance Biopharma, Inc. TBPH |
The Vanguard Group | 2,051,689 4.190% |
-1,437,573 (-41.20%) |
Filing |
| 2024-02-13 5:15 pm Sale |
2023-12-29 | 13G | Theravance Biopharma, Inc. TBPH |
The Vanguard Group | 3,489,262 7.010% |
-2,069,577 (-37.23%) |
Filing |
| 2023-02-09 11:35 am Sale |
2022-12-30 | 13G | Theravance Biopharma, Inc. TBPH |
The Vanguard Group | 5,558,839 8.250% |
-740,984 (-11.76%) |
Filing |
| 2022-02-10 08:42 am Purchase |
2021-12-31 | 13G | Theravance Biopharma, Inc. TBPH |
The Vanguard Group | 6,299,823 8.550% |
1,645,514 (+35.35%) |
Filing |
| 2021-02-10 11:57 am Purchase |
2020-12-31 | 13G | Theravance Biopharma, Inc. TBPH |
The Vanguard Group | 4,654,309 7.270% |
650,707 (+16.25%) |
Filing |